Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S 81694 and Paclitaxel in Metastatic Breast Cancer
NCT03411161Phase 2Completed
- Sponsor
- Servier
- Start
- Jan 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of s 81694 in breast cancer, triple negative breast cancer (TNBC), sponsored by Servier. Started Jan 2018; status: completed.
02
Drugs
s 81694
03
Conditions
breast cancertriple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03411161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03411161.